NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.20 -0.09 (-2.74 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$3.20
Today's Range$3.1560 - $3.30
52-Week Range$2.14 - $4.71
Volume9.34 million shs
Average Volume2.61 million shs
Market Capitalization$523.46 million
P/E Ratio-5.16
Dividend YieldN/A
Beta1.36

About Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.14
Quick Ratio5.14

Price-To-Earnings

Trailing P/E Ratio-5.16
Forward P/E Ratio-4.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.48 million
Price / Sales116.84
Cash FlowN/A
Price / CashN/A
Book Value$0.69 per share
Price / Book4.64

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-77,990,000.00
Net MarginsN/A
Return on Equity-113.73%
Return on Assets-92.96%

Miscellaneous

Employees103
Outstanding Shares163,580,000

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.17). During the same period in the prior year, the firm earned ($0.13) earnings per share. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

5 equities research analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $8.30 in the next year. View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (5/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "Premature to Write-off IgAN for Now. Given the totality of the data and unmet need in IgAN, we have slightly lowered our probability of success for the program. While the data did not meet the primary endpoint of a statistically significant mean change in proteinuria from baseline, several positive trends were found among a pre-specified population of patients with greater than 1,000mg/g of proteinuria. Treatment with 150mg fostamatinib twice daily at 24-weeks led to a median reduction in proteinuria from baseline of 803mg/ g (n=15), compared with 100mg fostamatinib’s reduction of 720mg/g (n=16) and placebo’s reduction of 177mg/g (n=14). These trends were also observed among patients who entered the study with a baseline proteinuria of 2,000mg/g. During the study safety events were in-line with previous experiences, with two patients experiencing severe adverse events across each cohort and two events reported as drug related (pancreatitis and abnormal liver enzyme). As a reminder, fostamatinib has over 5,000 patient-years of experience generated with the drug. Going forward, Rigel plans to advance the IgAN program through collaborations with a pharmaceutical partner, which we believe could be potentially bundled with an ex-U.S. territory licensing of TAVLISSE for lead indication ITP." (4/3/2018)

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 57)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 59)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Thomas A. Raffin, Co-Founder (Age 71)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

Media headlines about RIGL stock have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a coverage optimism score of 0.06 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.77%), Palo Alto Investors LP (2.42%), Rock Springs Capital Management LP (1.57%), JPMorgan Chase & Co. (1.24%), Northern Trust Corp (1.09%) and Candriam Luxembourg S.C.A. (0.92%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Donald G Payan and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., DAFNA Capital Management LLC and Teacher Retirement System of Texas. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Ryan D Maynard. View Insider Buying and Selling for Rigel Pharmaceuticals.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Candriam Luxembourg S.C.A., UBS Group AG, Rock Springs Capital Management LP, A.R.T. Advisors LLC and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.20.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $523.46 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Rigel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.30, suggesting that the stock has a possible upside of 159.38%. The high price target for RIGL is $10.00 and the low price target for RIGL is $7.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.30$8.30$6.00$5.75
Price Target Upside: 159.38% upside109.60% upside42.52% upside61.06% upside

Rigel Pharmaceuticals (NASDAQ:RIGL) Consensus Price Target History

Price Target History for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00HighView Rating Details
5/2/2018HC WainwrightLower Price TargetBuy ➝ Buy$8.00 ➝ $7.50HighView Rating Details
5/1/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Overweight$6.00 ➝ $9.00HighView Rating Details
5/1/2018Piper Jaffray CompaniesBoost Price TargetOverweight$7.00 ➝ $8.00HighView Rating Details
4/18/2018Jefferies Financial GroupBoost Price TargetBuy$7.00HighView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingBuy$5.00N/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings History and Estimates Chart

Earnings by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.65)
2019 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.18)($0.18)($0.18)
Q2 20182($0.16)($0.16)($0.16)
Q3 20182($0.16)($0.15)($0.16)
Q4 20182($0.15)($0.15)($0.15)
Q1 20191($0.14)($0.14)($0.14)
Q2 20191($0.12)($0.12)($0.12)
Q3 20191($0.11)($0.11)($0.11)
Q4 20191($0.09)($0.09)($0.09)

Rigel Pharmaceuticals (NASDAQ RIGL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.16)N/AView Earnings Details
5/1/2018Q1 2018($0.17)($0.17)$0.20 millionViewListenView Earnings Details
3/6/2018Q4 2017($0.13)($0.18)$0.05 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.15)($0.14)$0.90 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.15)($0.16)$2.05 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.12)($0.13)$4.30 million$3.58 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.17)($0.16)$4.25 million$3.00 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.24)$3.97 million$3.76 millionViewListenView Earnings Details
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)$1.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.36)($0.33)ViewN/AView Earnings Details
11/2/2010Q3 2010$0.58$0.96ViewN/AView Earnings Details
8/3/2010Q2 2010$0.45$0.52ViewN/AView Earnings Details
5/4/2010Q1 2010($0.06)($0.43)ViewN/AView Earnings Details
3/2/2010Q4 2009($0.45)($0.48)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.56)($0.70)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.80)($0.81)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.97)($0.80)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.96)($0.91)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.75)($1.03)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.66)($0.93)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.58)($0.79)ViewN/AView Earnings Details
2/12/2008Q4 2007($0.44)($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rigel Pharmaceuticals (NASDAQ:RIGL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.38%
Institutional Ownership Percentage: 84.51%
Insider Trading History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ RIGL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2018Anne-Marie DuliegeEVPSell5,000$4.11$20,550.00View SEC Filing  
11/3/2017Ryan D MaynardCFOSell100,000$3.90$390,000.00100,000View SEC Filing  
7/5/2017Anne-Marie DuliegeInsiderSell5,000$2.69$13,450.00View SEC Filing  
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rigel Pharmaceuticals (NASDAQ RIGL) News Headlines

Source:
DateHeadline
Rigel Pharmaceuticals, Inc. (RIGL) Expected to Post Quarterly Sales of $300,000.00Rigel Pharmaceuticals, Inc. (RIGL) Expected to Post Quarterly Sales of $300,000.00
www.americanbankingnews.com - June 13 at 2:52 AM
Rigel Pharma (RIGL) to Present Phase 2 Results for Fostamatinib in AIHA at EHA MeetingRigel Pharma (RIGL) to Present Phase 2 Results for Fostamatinib in AIHA at EHA Meeting
www.streetinsider.com - June 12 at 9:09 AM
Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHARigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
finance.yahoo.com - June 12 at 9:09 AM
-$0.16 Earnings Per Share Expected for Rigel Pharmaceuticals, Inc. (RIGL) This Quarter-$0.16 Earnings Per Share Expected for Rigel Pharmaceuticals, Inc. (RIGL) This Quarter
www.americanbankingnews.com - June 11 at 3:18 PM
Reader Inquiry: Is Rigel Pharmaceuticals Due For A Near Term Breakout?Reader Inquiry: Is Rigel Pharmaceuticals Due For A Near Term Breakout?
seekingalpha.com - June 11 at 9:11 AM
GALAPAGOS NV/S (GLPG) versus Rigel Pharmaceuticals (RIGL) Critical ReviewGALAPAGOS NV/S (GLPG) versus Rigel Pharmaceuticals (RIGL) Critical Review
www.americanbankingnews.com - June 6 at 3:28 PM
Rigel Pharmaceuticals (RIGL) vs. Bayer (BAYRY) Head-To-Head AnalysisRigel Pharmaceuticals (RIGL) vs. Bayer (BAYRY) Head-To-Head Analysis
www.americanbankingnews.com - June 5 at 5:18 AM
Rigel Pharmaceuticals, Inc. (RIGL) Given Average Recommendation of "Buy" by BrokeragesRigel Pharmaceuticals, Inc. (RIGL) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 4 at 11:32 AM
Rigel to Present at Jefferies 2018 Global Healthcare ConferenceRigel to Present at Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 31 at 9:41 AM
Rigel Pharma (RIGL) Appoints Dean Schorno as CFORigel Pharma (RIGL) Appoints Dean Schorno as CFO
www.streetinsider.com - May 30 at 4:33 PM
Rigel Pharma (RIGL) Announces Availability of TAVALISSE in the U.S.Rigel Pharma (RIGL) Announces Availability of TAVALISSE in the U.S.
www.streetinsider.com - May 29 at 4:30 PM
Rigel Announces Availability Of TAVALISSE - Quick FactsRigel Announces Availability Of TAVALISSE - Quick Facts
www.nasdaq.com - May 29 at 9:14 AM
Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
finance.yahoo.com - May 29 at 9:14 AM
Zacks: Brokerages Expect Rigel Pharmaceuticals, Inc. (RIGL) to Announce -$0.16 EPSZacks: Brokerages Expect Rigel Pharmaceuticals, Inc. (RIGL) to Announce -$0.16 EPS
www.americanbankingnews.com - May 25 at 5:20 AM
Rigel Pharmaceuticals, Inc. Expected to Post FY2018 Earnings of ($0.66) Per Share (RIGL)Rigel Pharmaceuticals, Inc. Expected to Post FY2018 Earnings of ($0.66) Per Share (RIGL)
www.americanbankingnews.com - May 24 at 8:23 AM
Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Decreases By 18.3%Short Interest in Rigel Pharmaceuticals, Inc. (RIGL) Decreases By 18.3%
www.americanbankingnews.com - May 12 at 2:11 AM
Rigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Buy" by BrokeragesRigel Pharmaceuticals, Inc. (RIGL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 4:37 PM
Rigel Pharmaceuticals (RIGL) Stock Rating Upgraded by Zacks Investment ResearchRigel Pharmaceuticals (RIGL) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:11 PM
Rigel Pharmaceuticals, Inc. (RIGL) Expected to Announce Quarterly Sales of $300,000.00Rigel Pharmaceuticals, Inc. (RIGL) Expected to Announce Quarterly Sales of $300,000.00
www.americanbankingnews.com - May 9 at 2:00 AM
Zacks: Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Post Earnings of -$0.16 Per ShareZacks: Analysts Expect Rigel Pharmaceuticals, Inc. (RIGL) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 7 at 9:14 PM
Rigel Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call SlidesRigel Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 4:28 PM
FY2018 EPS Estimates for Rigel Pharmaceuticals, Inc. (RIGL) Reduced by Piper JaffrayFY2018 EPS Estimates for Rigel Pharmaceuticals, Inc. (RIGL) Reduced by Piper Jaffray
www.americanbankingnews.com - May 4 at 8:15 AM
Brokers Set Expectations for Rigel Pharmaceuticals, Inc.s Q2 2018 Earnings (RIGL)Brokers Set Expectations for Rigel Pharmaceuticals, Inc.'s Q2 2018 Earnings (RIGL)
www.americanbankingnews.com - May 4 at 7:30 AM
Rigel Pharmaceuticals (RIGL) Releases Quarterly  Earnings Results, Hits ExpectationsRigel Pharmaceuticals (RIGL) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - May 2 at 2:52 PM
Rigel Pharmaceuticals (RIGL) Given Buy Rating at HC WainwrightRigel Pharmaceuticals (RIGL) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - May 2 at 11:10 AM
Rigel Pharmaceuticals (RIGL) Given New $10.00 Price Target at BMO Capital MarketsRigel Pharmaceuticals (RIGL) Given New $10.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - May 2 at 10:44 AM
Cantor Fitzgerald Reiterates $9.00 Price Target for Rigel Pharmaceuticals (RIGL)Cantor Fitzgerald Reiterates $9.00 Price Target for Rigel Pharmaceuticals (RIGL)
www.americanbankingnews.com - May 2 at 10:25 AM
Rigel Pharmaceuticals up 4% on Q1 resultsRigel Pharmaceuticals up 4% on Q1 results
seekingalpha.com - May 2 at 9:22 AM
Rigel Pharmaceuticals (RIGL) CEO Raul Rodriguez on Q1 2018 Results - Earnings Call TranscriptRigel Pharmaceuticals (RIGL) CEO Raul Rodriguez on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 9:22 AM
Edited Transcript of RIGL earnings conference call or presentation 1-May-18 9:00pm GMTEdited Transcript of RIGL earnings conference call or presentation 1-May-18 9:00pm GMT
finance.yahoo.com - May 2 at 9:22 AM
Rigel: 1Q Earnings SnapshotRigel: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 9:22 AM
Rigel Pharmaceuticals (RIGL) Given New $8.00 Price Target at Piper JaffrayRigel Pharmaceuticals (RIGL) Given New $8.00 Price Target at Piper Jaffray
www.americanbankingnews.com - May 1 at 9:18 PM
Rigel Announces First Quarter 2018 Financial Results and Provides Company UpdateRigel Announces First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - May 1 at 4:27 PM
Rigel Pharma (RIGL) Says TAVALISSE Phase 3 Data Published in American Journal of Hematology Describes Pivotal ...Rigel Pharma (RIGL) Says TAVALISSE Phase 3 Data Published in American Journal of Hematology Describes Pivotal ...
www.streetinsider.com - April 30 at 9:36 AM
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus PlaceboTAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
finance.yahoo.com - April 30 at 9:36 AM
The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On TapThe Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap
www.benzinga.com - April 29 at 9:41 AM
Rigel Pharmaceuticals, Inc. (RIGL) Expected to Earn Q2 2018 Earnings of ($0.16) Per ShareRigel Pharmaceuticals, Inc. (RIGL) Expected to Earn Q2 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - April 27 at 7:46 AM
Rigel Pharmaceuticals Is In Bargain TerritoryRigel Pharmaceuticals Is In Bargain Territory
seekingalpha.com - April 25 at 4:39 PM
Rigel Pharmaceuticals, Inc. (RIGL) EVP Sells $20,550.00 in StockRigel Pharmaceuticals, Inc. (RIGL) EVP Sells $20,550.00 in Stock
www.americanbankingnews.com - April 24 at 10:22 PM
Rigel Gets A Surprise Approval For TavalisseRigel Gets A Surprise Approval For Tavalisse
seekingalpha.com - April 24 at 4:43 PM
Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial ResultsRigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
www.bizjournals.com - April 24 at 9:24 AM
Rigel Pharmaceuticals (RIGL) to Release Quarterly Earnings on MondayRigel Pharmaceuticals (RIGL) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 7:50 AM
Rigel Pharmaceuticals (RIGL) FDA Approval Of TAVALISSE(TM) - SlideshowRigel Pharmaceuticals (RIGL) FDA Approval Of TAVALISSE(TM) - Slideshow
seekingalpha.com - April 20 at 4:32 PM
Rigel prices stock offering at $3.90; shares up 1% premarketRigel prices stock offering at $3.90; shares up 1% premarket
seekingalpha.com - April 20 at 9:36 AM
Jefferies Group Research Analysts Raise Earnings Estimates for Rigel Pharmaceuticals, Inc. (RIGL)Jefferies Group Research Analysts Raise Earnings Estimates for Rigel Pharmaceuticals, Inc. (RIGL)
www.americanbankingnews.com - April 20 at 8:52 AM
Rigel Pharma (RIGL) Reports FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune ThrombocytopeniaRigel Pharma (RIGL) Reports FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia
www.streetinsider.com - April 19 at 9:26 AM
2 Bay Area drug approvals in 1 day underscore industrys issues, opportunities2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
www.bizjournals.com - April 18 at 4:46 PM
Rigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA ApprovalRigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA Approval
www.streetinsider.com - April 18 at 4:46 PM
Analysts See 100% Upside To Rigel After Tavalisse ApprovalAnalysts See 100% Upside To Rigel After Tavalisse Approval
finance.yahoo.com - April 18 at 4:45 PM
2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
finance.yahoo.com - April 18 at 4:45 PM

SEC Filings

Rigel Pharmaceuticals (NASDAQ:RIGL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rigel Pharmaceuticals (NASDAQ:RIGL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rigel Pharmaceuticals (NASDAQ RIGL) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.